相关实验视频
Updated: Jun 17, 2025

06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
35.1K
升高的LAMTOR4表达与致死性前列腺癌有关,并且其杀降低了细胞增殖,入侵和细胞迁移在体外
Yaser Gamallat1,2,3, Huseen Alwazan1, Rasoul Turko1
1Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
International journal of molecular sciences
|August 10, 2024
概括
在前列腺癌患者中,高LAMTOR4蛋白表达与较差的生存结果相关. 在前列腺癌细胞中抑制LAMTOR4可减少扩散和转移,这表明它是治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 拉姆托 (LAMTOR) 复合体 (晚期内体/溶体适配器,MAPK和mTOR) 集成生长因子信号和营养感应.
- 在瘤发生,特别是前列腺癌中LAMTOR4的特定作用仍然在很大程度上未被探索.
- LAMTOR4可能在瘤细胞增殖和转移中发挥作用.
研究的目的:
- 研究前列腺癌中LAMTOR4的蛋白质表达 (PCa).
- 为了将LAMTOR4表达与基因组状态 (ERG,PTEN) 和临床病理特征相关联.
- 在体外探索LAMTOR4在PCa细胞行为和相关途径中的功能作用.
主要方法:
- 在314个前列腺切除样本中分析LAMTOR4的蛋白质表达.
- 与ERG和PTEN基因组状态,格里森得分和患者存活率的相关性.
- 在前列腺癌细胞系中LAMTOR4的体外淘汰和通过TCGA-PRAD进行mRNA表达分析.
主要成果:
- 高LAMTOR4蛋白表达与较差的整体存活率 (OS) 和因果特异性存活率 (CSS) 显著相关.
- 结合高LAMTOR4表达与PTEN阴性状态或ERG阳性状态进一步恶化患者的生存结果.
- 抑制LAMTOR4降低了PCa细胞的增殖,迁移和入侵,并失调了β-catenin/mTOR通路.
结论:
- 拉姆托尔4是前列腺癌的潜在预后生物标志物.
- 拉姆托尔4在促进前列腺癌进展和转移方面发挥着重要作用.
- 准LAMTOR4或mTOR通路为前列腺癌提供了一个潜在的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K

